CUTERA Says FDA Clears AviClear As Long-Term Treatment For Mild To Severe Acne
(RTTNews) - Dermatology solutions provider CUTERA, INC. (CUTR) announced Thursday a new U.S. Food and Drug Administration clearance of AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. This is the first acne therapy to claim long term effectiveness for mild, moderate and severe acne.
AviClear initially received FDA clearance in March 2022 following an extensive clinical trial. Now after months of clinical data evaluation, the FDA has additionally recognized AviClear as a clinically efficacious and proven treatment for the long-term treatment of acne.
AviClear selectively targets and suppresses the sebaceous glands, eliminating acne at the source, offering a durable and prescription free option for patients and providers.
As the first 1726nm laser to be introduced to the market, AviClear continues to challenge the status quo in the acne landscape.
In three, 30-minute treatment sessions 90% of patients experienced visible improvement in their acne six months after their third session. According to 12-month clinical data, improvement increases to 92%, confirming long-term efficacy of acne clearance and skin quality over time.
U.S. Dollar Falls Against Most Majors
German Inflation Accelerates To 2.2% In August
Canadian Market Up In Positive Territory; BRP Rises Sharply On Strong Earnings
Swiss Market Ends Modestly Lower
European Stocks Close Lower On Geopolitical Tensions
U.S. Consumer Sentiment Deteriorates Slightly More Than Initially Estimated In August
Chicago Business Barometer Slumps Much More Than Expected In August
